Skip to main content
Schott Pharma logo

Schott Pharma — Investor Relations & Filings

Ticker · 1SXP ISIN · DE000A3ENQ51 LEI · 529900TU48UE99NHEY88 F Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2024-07-16 Regulatory Filings
Country DE Germany
Listing F 1SXP

About Schott Pharma

https://www.schott-pharma.com/en

Schott Pharma is a developer and manufacturer of drug containment solutions and delivery systems for injectable drugs. Serving the pharmaceutical and biotech industries, its portfolio includes prefillable syringes, cartridges, vials, and ampoules. The company provides scientifically proven products designed for the safe storage and administration of medications. Beyond individual components, Schott Pharma offers complete, compatible systems and a range of services, including analytical, development, fill-and-finish, and regulatory support. This integrated approach supports clients from clinical trials through to commercialization, ensuring compatibility across the entire pharma value chain.

Recent filings

Filing Released Lang Actions
Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
Regulatory Filings Classification · 1% confidence The document is a news release dated July 16, 2024, announcing a 'Market Launch' by SCHOTT Pharma AG & Co. KGaA regarding new 10ml ready-to-use (RTU) cartridges for on-body devices. It uses the EQS-News distribution service, which typically disseminates corporate news, press releases, or regulatory announcements. Since this is a specific announcement about a product launch and partnership, it is not a formal financial report (like 10-K or IR), nor is it a transcript (CT) or a dividend notice (DIV). It is a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news release that doesn't fit the highly specific financial or governance categories, as it is a standard market announcement disseminated via a news service.
2024-07-16 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in the percentage of voting rights held by T. Rowe Price entities in SCHOTT Pharma AG & Co. KGaA, referencing Article 40, Section 1 of the WpHG (German Securities Trading Act). This type of filing, which reports changes in significant share ownership crossing specific thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory announcement, MRQ is a more specific category than the general RNS.
2024-07-04 English
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Earnings Release Classification · 1% confidence The document text explicitly states it contains key financial highlights for the second quarter of fiscal year 2024, using phrases like 'SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024' and includes the keyword 'Half Year Report/Half Year Results' in the EQS header. It provides summarized financial figures (Revenues, EBITDA margin) for Q2 and H1 2024, which is characteristic of an initial results announcement rather than the comprehensive report itself (10-K or IR). Furthermore, it mentions a webcast to discuss the 'Q2 2024 results'. This strongly indicates an Earnings Release (ER). Although it mentions 'Half Year Report', the format is a news release summarizing results, not the full report, making ER the most appropriate classification for this initial disclosure. Q2 2024
2024-06-27 English
Half-yearly financial report 2023/2024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Half-year Financial Report' for SCHOTT Pharma covering the period from 1 October 2023 to 31 March 2024. It contains comprehensive financial statements, including the Consolidated Statement of Income, Statement of Financial Position, and Statement of Cash Flows, along with an Interim Group Management Report. It is a full interim report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-06-27 English
Presentation H1 2023/2024
Earnings Release Classification · 1% confidence The document is titled 'Q2/H1 2024 Results presentation' and features sections like 'Strategy & Business Update' and 'Financial Update' presented by the CEO and CFO. It explicitly discusses financial figures for Q2 2024, revenue, EBITDA margin, guidance confirmation for FY 2024, and outlook. This content structure is characteristic of an Earnings Release (ER) or a presentation accompanying one, rather than a comprehensive statutory report (10-K or IR). Since it is a presentation summarizing period results, Investor Presentation (IP) is a strong candidate, but given the explicit focus on period results ('Q2/H1 2024 Results presentation') and guidance confirmation, it aligns best with the initial announcement of results, which is the Earnings Release (ER). It is not a full transcript (CT) or a comprehensive statutory report (10-K/IR). It is a presentation accompanying the results announcement. H1 2024
2024-06-27 English
Präsentation H1 2023/2024 (englisch)
Investor Presentation Classification · 1% confidence The document is titled 'Q2/H1 2024 Results presentation' and features sections like 'Strategy & Business Update' and 'Financial Update' presented by the CEO and CFO. It details key financial figures for Q2 2024, revenue growth, EBITDA margin, cash generation, and confirms guidance for fiscal 2024. This structure—a presentation summarizing periodic financial results, strategy, and outlook—is characteristic of an Investor Presentation (IP), often used in conjunction with an Earnings Release (ER) but distinct from the formal ER document itself. Since it is a detailed presentation summarizing results and strategy, 'Investor Presentation' (IP) is the most appropriate classification over a simple 'Earnings Release' (ER) which usually contains only the highlights.
2024-06-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.